A Look into Clinical Chemistry Analyzers Industry……Deep Analysis…..



The global clinical chemistry analyzers market size is expected to reach USD 16.0 billion by 2025, according to a new study by Grand View Research, Inc. The growing prevalence of chronic diseases is anticipated to be responsible for the high urgency to adopt clinical chemistry analyzers, which thereby widens the scope for growth during the forecast period. In addition, growing base of geriatric and bariatric population, which is highly susceptible to chronic diseases, is presumed to impel the demand further. Consequently, the resultant high sample volume requiring high capability analyzing devices is driving the market growth.
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
Moreover, increasing awareness pertaining to benefits associated with these devices is also a high impact rendering driver for clinical chemistry analyzers market. Advent of advanced chemistry analyzers has resulted in improved point-of-care testing capabilities, and thus created high potential growth opportunities for the market. In addition, technological advancements in preanalytical, analytical, and post analytical stages due to analyzing devices & reagents improved their diagnostic capabilities and overall efficiency, which is predicted to propel the growth further. These advancements include advent of microchips, sensors, chemometrics, and robotics. Furthermore, consistent efforts by public as well private healthcare organizations to increase the reliability of data have rapidly engendered the integration of automated chemistry analyzers and immunoassay systems, thereby resulting in overall reduction of workload in laboratories, thus propelling the demand.
To Request Sample Copy of this report, click the link:
Further Key Findings From the Study Suggest:
·         Reagents held a substantial share in product segment in 2015. The substantial share can be attributed to increasing reagent rental agreements and availability resulting in quick global access
·         Lipid panel is anticipated to exhibit lucrative CAGR during the forecast period owing to increasing adoption, as the demand for screening tests for cholesterol and triglyceride levels in case of cardiovascular disorders and diabetes has increased
·         In 2016, North America accounted for substantial share in the global clinical chemistry analyzers market, as a consequence of local presence of prominent companies involved in high R&D investments
·         Asia Pacific is anticipated to grow at an exponential CAGR due to unmet patient needs, continuous technological & infrastructural upgradation, and growing healthcare expenditure
·         Some key participants such as Mindray Medical International Ltd.; Johnson & Johnson; and F.Hoffmann-La Roche Ltd. are undertaking various sustainability strategies, such as new product development & frequent product approvals, to gain competitive advantage
·         For instance, in August 2016, Mindray announced the premarket FDA clearance for Mindray BA-800M clinical chemistry analyzer allowing it to distribute its product
The global clinical chemistry analyzers market accounted for USD 9.9 billion in 2016 and is expected to grow at a CAGR of 5.5% during the forecast period. The increasing prevalence of chronic diseases, such as diabetes, is predicted to be one of the high impact rendering drivers of this market. This subsequent increase in disease prevalence has triggered companies to produce advanced analyzers at a large scale, to aid in diagnosis. Consequently, the high need for chemistry analyzers led to an unprecedented growth in new market entrants, resulting in high competition.
The technological innovations in clinical chemistry analyzers have led to early disease detection and specialized diagnosis in the areas of oncology, gynecology, & endocrinology and enabled testing on a larger scale. The advancements comprise advanced modeling & parameter estimation, better resolution, improved pattern recognition, computer-assisted interpretation, and artificial intelligence.
The benefits of abovementioned advancements and automated analyzers are automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment. These tools also offer analysis of wide range of samples and facilitate immediate generation of results, reflecting their potential applications in intensive care unit, outpatient clinics, and emergency as well as surgical wards in future. These benefits are estimated to drive physician preference for these analyzers, thus creating high potential opportunities for growth during the forecast period.
Have any Query? Ask our Experts:
Reagents accounted for the largest share in the product segment in 2015. The substantial share is predicted to be a consequence of wide array of reagents present in the market, catering to different requirements of clinicians. These reagents predominantly include enzymes, substrates, specific proteins, electrolytes, lipids and others, which are imperative to obtain accurate results in analytical procedures.
In addition, reagents are believed to be highly cost efficient, possess optimum sensitivity, linearity, and precision, which thereby, ensures minimized performance variation. The aforementioned benefits are predicted to be highly responsible for encouraging clinicians to use reagents for accurate diagnosis.
Grand View Research has segmented the global clinical chemistry analyzers market on the basis of product, test, end use, and region:
Clinical Chemistry Analyzers Product Outlook (Revenue, USD Million, 2014 - 2025)
·         Analyzers
o    Small
o    Medium
o    Large
o    Others
·         Reagents
o    Calibrators
o    Controls
o    Standards
o    Others
·         Others
Clinical Chemistry Analyzers Test Outlook (Revenue, USD Million, 2014 - 2025)
·         Basic Metabolic Panel(BMP)
·         Electrolyte Panel
·         Liver Panel
·         Lipid Profile
·         Renal Profile
·         Thyroid Function Panel
·         Specialty Chemical Tests
Clinical Chemistry Analyzers End-Use Outlook (Revenue, USD Million, 2014 - 2025)
·         Hospitals
·         Academic Research Centers
·         Diagnostic Laboratories
·         Others
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.




Comments

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

A Look into Smokehouse Industry……Deep Analysis…..

A Look into Shapewear Industry……Deep Analysis…..